Cost Associated with Healthcare Resource Utilization Reduced with Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in High-Risk Liver Transplant Recipients (ATC 2026) - Jun 17, 2026 - Abstract #Abstract B360; Pres time: Jun 21, 2026; 02:45 PM - 03:45 PM; Location: Exhibit Hall; "Using a small population of high-risk LTRs receiving de novo LTV at our center, cost burden associated with HCRU during prophylaxis was significantly reduced compared to VGC. While AWP of LTV is currently higher than VGC, a comparison evaluating drug cost alone is inadequate and true cost effectiveness of LTV after SOT remains largely unknown. The US healthcare payor model is complex given the mix of payers and separation of medical and pharmacy benefits."
Clinical • HEOR • Cytomegalovirus Infection • Solid Organ Transplantation • Transplantation
|
|
H. Kleiboeker 1; J. Fose 2; C. Saddler 2; D. Al-Adra 2; J. Rice 2; M. Jorgenson 3
|